### **Overview** Remus Pharmaceuticals Ltd, founded in 2015, is a fast-growing, asset-light pharmaceutical company specializing in the branding, marketing, and global distribution of complex specialty and niche off-patent formulations. With a presence in over 40 countries across Latin America, Africa, Southeast Asia, the Middle East, CIS, and increasingly in developed markets, Remus combines regulatory agility, strategic branding, and scalable B2B and B2C models to achieve rapid market entry and sustainable growth. The company operates through a lean, capital-efficient model, relying on a network of over 30 contract development and manufacturing organizations (CDMOs/CMOs) for production, while maintaining control over high-value regulatory dossiers, branding, and commercialization. Key subsidiaries include: - **Relius Pharma SRL** (Bolivia) – B2C-focused direct-to-consumer arm. - **Espee Global Holdings LLC** (USA) – A U.S.-based subsidiary acquired in 2024 that acts as a major distributor of Reference Listed Drugs (RLDs), REMS, specialty, orphan, and biosimilar drugs via an FDA-approved facility. The corporate structure includes a stepdown subsidiary, **Espee Biopharma & Fine Chem LLC**, reflecting a strategic tiered architecture for international operations and product development. --- ### **Business Model & Strategy** #### **Asset-Light & Scalable Operations** Remus operates with minimal capital investment in manufacturing, avoiding inventory and promotional expenses. It leverages third-party manufacturers with international accreditations and implements rigorous quality assurance processes (batch validation, stability studies, packaging integrity) to ensure compliance and product safety. The company utilizes a single, standardized dossier for multiple country submissions, accelerating regulatory approvals and reducing time-to-market. #### **Dual Revenue Streams: B2B and B2C** - **B2B Segment**: Offers end-to-end regulatory and commercial solutions to global pharma partners, enabling rapid market entry in semi-regulated and emerging markets. This includes product registration support, technical consultancy, and participation in government and institutional tenders. - **B2C Segment (via Relius Brand)**: Targets direct consumers through pharmacy networks and last-mile delivery in Latin America (Bolivia, Guatemala). Currently contributes **13% of total revenue**, with a strategic target of **20–25% within 1.5 years** due to higher margins and stronger brand equity. The B2C model allows Remus to capture the full value chain, enabling premium pricing in commoditized markets. EBITDA margins in B2B operations in Latin America stand at **32–33%**, with B2C expected to further enhance profitability. --- ### **Product Portfolio & R&D Focus** - **Over 2,000 SKUs** across diverse therapeutic areas: - Cardiovascular - Neurology - Hematology - Anti-infectives - Oncology - Diabetic therapies - Critical care **Dosage Forms**: Tablets, capsules, injectables (lyophilized and pre-filled syringes), inhalers, nasal sprays, ophthalmic products, topicals, syrups, and more. - **Regulatory Pipeline (as of Nov 2025)**: - **620+ approved products** - **640+ under evaluation by Ministries of Health** - **745+ dossiers ready for submission** - Over **37 new approvals secured in ASEAN (Myanmar)** and ongoing filings in **Algeria, Bosnia, Kosovo, Mexico, Tanzania**, and others. - **Innovation Strategy**: - Focus on **niche, first-to-market off-patent drugs** with limited competition and extended commercial life. - Prioritizes advanced formulations: **extended-release tablets**, **pre-filled syringes (PFS)**, **bi-layer products**, **liposomal injections**, and **fixed-dose combinations**. - R&D team of **60+ scientists**, including 30+ formulation experts, capable of developing and scaling **200+ new products annually**. - **Key Molecules in Development**: - Semaglutide (Ozempic) for weight management. - Complex generics in oncology, neurology, and biosimilars. Remus plans to launch **2,000 new products over the next three years**, with **800–1,000 from in-house R&D** and over **2,000 product registrations** filed globally. --- ### **Geographic Expansion & Market Access** #### **Core Markets & Presence** - Operates in **40+ countries**, with strong footholds in: - **Latin America** (Bolivia, Guatemala, Nicaragua, Peru, El Salvador, Chile, Ecuador, Dominican Republic) - **ASEAN** (Myanmar, Vietnam, Cambodia, Bhutan) - **Middle East & North Africa** (Kuwait, Saudi Arabia, Algeria, Mauritania) - **Eastern Europe & CIS** (Azerbaijan, Bosnia, Kosovo) - **Sub-Saharan Africa** (Kenya, Tanzania, Madagascar) #### **Strategic Expansion (2024–2025)** - **U.S. Entry (2024)**: Acquisition of **Espee Global Holdings LLC** established a U.S. distribution hub serving **300+ clients across 30+ countries**, enhancing access to RLDs and clinical trial supply. - **Singapore Branch Office**: Being established as a regional operational hub for Asia, replacing earlier plans for Dubai. - **New Market Entry Plans**: Targeting **Mexico, Algeria, Bosnia, Ethiopia, Kosovo, and Tanzania** via accelerated product registrations. - **Local Incorporations**: Direct subsidiaries now in **Bolivia and Guatemala** for enhanced control, compliance, and market penetration. #### **Tender Strategy** - Active participation in **national and institutional tenders**, submitting **20 products per country** in locations like Nicaragua (where it secured **2 product awards**), Kuwait, Mauritania, and Venezuela. - Specialization in **oncology, orphan drugs, and specialty biosimilars** gives competitive edge in high-complexity categories. --- ### **Branding & Commercialization** - **Relius Brand**: - Dedicated B2C platform launched in **Bolivia and Guatemala**. - Over **15 products launched in Bolivia**, including **Rivaroxaban 10 mg**, **Eltrombopag 25 mg**, **Carbidopa + Levodopa**, and **Cefepime 1 g Injection**. - Expanded into Chile, Peru, El Salvador, Myanmar, and Africa with marketing and brand authorization processes underway. - **Product Awards & Milestones**: - Successful launch of **Rivastigmine Patch**, marking entry into **neurology therapeutics**. - Commercialization of **over 115 products in Venezuela**; **35+ oncology products** approved for Q4 launch. - **50 new product launches under Relius** between 2023–2024. - **Brand Building**: - **170+ trademarks filed globally**, with over **35 approvals secured** (May 2025). - **Medical engagement programs** conducted with 60+ top-tier doctors and specialists (e.g., gynecologists, hematologists). - Hosted medical conferences (e.g., Bolivia, 55+ participants) to build prescriber trust and adoption. --- ### **Regulatory & Operational Strength** - **In-House Regulatory Team**: **30+ experts** handling filings for complex categories (oncology, biosimilars, mAbs, peptides) across **40+ emerging markets**. - **Filing Velocity**: Submits **over 50 dossiers per month**, with proactive, simultaneous submissions across geographies. - **Compliance Tools**: Uses **advanced ERP systems** and customized dashboards for regulatory tracking, trend analytics, and logistics oversight. - **Challenges Mitigated**: Navigates fragmented regulatory environments through standardized processes, pre-submission engagement, and bioequivalence/clinical studies. --- ### **Global Supply Chain & Capabilities** - **World’s Leading Distributor of RLDs**: Via Espee USA, supplies hard-to-find **REMS, specialty, orphan, and biosimilar drugs** for R&D, clinical trials, and commercial use. - **Advanced Logistics**: Full international delivery support with compliant, temperature-controlled, and trackable shipments. - **Diversified Network**: Partnerships with **150+ distributors**, **8+ pharmacy chains**, and **sub-distributors** to optimize reach in semi-regulated markets. --- ### **Financial & Growth Highlights** - **Revenue & Growth**: - FY 2023–2024: **$55.9 million in sales** (17% YoY growth from $47.19M in FY2021–22). - Strong trajectory supported by new market entries, tender wins, and B2C expansion. - **Capital Strategy**: - Completed **IPO in May 2023**, a milestone enabling funding for global expansion. - Disciplined capital allocation, generating **high ROE through operational efficiency**. - **Profitability Outlook**: - B2C growth and advanced formulations expected to drive **margin expansion**. - **Low working capital needs** due to inventory-free model.